Comparative Study
Journal Article
Add like
Add dislike
Add to saved papers

Comparison of the pharmacokinetic profiles of two oral controlled-release morphine formulations in healthy young adults.

The pharmacokinetic profiles of two oral controlled-release morphine formulations, MS Contin tablets and Roxanol SR tablets, were compared to evaluate their bioequivalence. In a sequential, crossover study, 18 healthy young male volunteers received single 60-mg doses (two 30-mg tablets) of each formulation and provided 15 serial blood samples over 24 hours, which were assayed to determine their morphine concentrations by high-performance liquid chromatography. Analysis of variance revealed significant differences between the treatments for maximum plasma concentration (P less than 0.001), area under the plasma concentration curve from zero to 12 hours (P less than 0.01), and apparent elimination half-life (P less than 0.001). No significant differences were found for time required to reach maximum plasma concentration and area under the plasma concentration-time curve from zero to 24 hours. The results show that the two morphine preparations are not bioequivalent.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app